

The logo for DiaSorin, featuring the company name in white serif font on a dark blue rectangular background.

## **DIASORIN S.P.A.: DEMAND WAS 3.3 TIMES THE SIZE OF THE OFFERING**

- The offering was extremely well received by investors responding positively to both the public offering and the institutional placement.
- Within the context of the institutional placement, demand was strong from investors both in Italy and abroad, particularly in the United States, Great Britain and France.

**Saluggia (Vercelli), July 17, 2007** – DiaSorin S.p.A., a company that operates in the global market for in vitro diagnostics developing, producing and marketing reagent kits for laboratory clinical diagnostics, announced the results of the Global Offering, which is being carried out to list its shares on the Star segment of the Online Stock Market organized and operated by Borsa Italiana.

The overall outcome of the offering of the DiaSorin shares demonstrates the significant interest with which the Company is being viewed not only by the public in general but also by institutional investors. Specifically, specialized investors, who are able to read the trends that shape the market in which DiaSorin operates, showed significant interest, indicating that they appreciate the Company' s strong balance sheet and, more importantly, the growth outlook it presented, supported by consolidated strategic guidelines and a highly transparent business model. In the institutional placement, there was healthy demand from Italian investors and strong interest from foreign invertors, particularly in the United States, France and Great Britain.

Specifically, the requests received in response to the Global Offering, which were filed by 10,521 applicants at the Offering Price, totaled 62,785,576 shares, broken down as follows:

- The requests received in response to the Public Offering, which were filed by 10,400 applicants, totaled 6,265,500 shares, broken down as follows:
  - 3,451,500 shares from 9,559 applicants who were part of the general public and requested Minimum Subscription Lots;
  - 2,814,000 shares from 841 applicants who were part of the general public and requested Minimum Expanded Subscription Lots;

- The requests received in response to the Institutional Placement, which were filed by 121 applicants, totaled 56,520,076 shares, broken down as follows:
  - 12,736,246 shares from 50 professional investors in Italy;
  - 43,783,830 shares from 71 institutional investors outside Italy.

Based on the requests received in response to the Global Offering, a total of 21,000,000 shares were allocated to 9,359 applicants. These shares included 19,000,000 offered for sale by the selling investors and 2,000,000 shares from the full exercise of the overallotment option. A breakdown is as follows:

- 3,800,100 shares were awarded to 9,247 applicants who responded to the Public Offering as follows:
  - 2,660,100 shares to 8,867 applicants who were part of the general public and requested Minimum Subscription Lots;
  - 1,140,000 shares to 380 applicants who were part of the general public and requested Minimum Expanded Subscription Lots;
- 17,199,900 shares were awarded to 112 applicants who responded to the Institutional Placement as follows:
  - 3,984,349 shares to 50 professional investors in Italy;
  - 13,215,551 shares to 62 institutional investors outside Italy.

The members of the Consortium for the Public Offering and the Consortium for the Institutional Placement were not required to subscribe any shares in performance of the commitments they had undertaken.

Mediobanca and UBS are the coordinators of the Global Offering and the Bookrunners. Mediobanca will also be responsible for the placement of the public offering and will be the transaction Sponsor and Specialist.

The Issuer's legal advisors are d'Urso Munari Gatti and, for international issues, Linklaters. The legal advisor for the Global Coordinator is Norton Rose.

Carlo Rosa, DiaSorin's Chief Executive Officer, stated:

*" The outcome of the Offering shows that DiaSorin is a company whose value is recognized both in Italy and abroad, particularly by specialized funds that appreciate the strength of our business*

*model and, understanding the potential of the market in which we operate, are confident in the growth prospects that we presented. We are proud of the successful response we received both in Italy and countries such as France, Great Britain and the United States, which are home to our most direct competitors.”*

\* \* \*

### **About DiaSorin**

DiaSorin S.p.A., an international player in the market for in vitro diagnostics, develops, produces and markets reagent kits for clinical laboratory diagnostics. The DiaSorin Group comprises 12 companies based in Europe, the United States, Central and South America. It has about 840 employees, including 70 research and development specialists, and operates three manufacturing and research facilities in Saluggia (Vercelli, Italy), Dietzenbach (Germany) and Stillwater (USA). Thanks to its direct sales organization and an international network of over 80 independent distributors, the Group is present in more than 60 countries, offering a broad array of high quality products that includes comprehensive lines for each of the clinical segments in which the Group operates: infectious and viral diseases, thyroid pathologies, oncology, fertility testing, etc.

---

#### **Contacts:**

Laura Villa

**DiaSorin S.p.A.**

Investor Relations Officer

[laura.villa@diasorin.it](mailto:laura.villa@diasorin.it)

+39 0161487532

+39 348 15 11 542

Pasquo Cicchini

**Hill & Knowlton**

[pcicchini@hillandknowlton.com](mailto:pcicchini@hillandknowlton.com)

+39 02 31914245

+39 335 6417880